HMGB1 and Stroke: In addition to the HMGB1 monoclonal antibody, it has now been found that histidine-rich glycoprotein (HRG) inhibits HMGB1 release and HMGB1-mediated neutrophil adhesion and endothelial barrier function to improve survival in septic mice, and further studies are needed to investigate the effect of HRG on the blood–brain barrier and as a new therapeutic option for stroke [159].